mutation predictions | marginal predictions | summary statistics | genome diff | command line log
|
breseq version 0.33.1 revision 8505477f25b3
mutation predictions | marginal predictions | summary statistics | genome diff | command line log |
| Marginal read alignment evidence (highest frequency 20 of 55 shown, sorted by frequency from high to low) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| seq id | position | ref | new | freq | score (cons/poly) | reads | annotation | genes | product | ||
| * | CP000730 | 35,970 | 0 | T | C | 63.4% | 265.5 / 282.8 | 280 | E194E (GAA→GAG) | tpn | IS431mec transposase |
| * | CP000730 | 76,295 | 0 | T | C | 63.1% | 197.9 / 235.7 | 245 | intergenic (+353/‑781) | USA300HOU_0072/USA300HOU_0075 | universal stress protein/lysophospholipase |
| * | CP000730 | 36,087 | 0 | A | G | 62.0% | 340.9 / inf | 403 | C155C (TGT→TGC) | tpn | IS431mec transposase |
| * | CP000730 | 76,322 | 0 | G | A | 61.9% | 143.5 / 258.2 | 232 | intergenic (+380/‑754) | USA300HOU_0072/USA300HOU_0075 | universal stress protein/lysophospholipase |
| * | CP000730 | 36,124 | 0 | G | A | 61.7% | 169.5 / inf | 308 | A143V (GCT→GTT) | tpn | IS431mec transposase |
| * | CP000730 | 76,353 | 0 | G | A | 58.8% | 95.9 / 216.9 | 177 | intergenic (+411/‑723) | USA300HOU_0072/USA300HOU_0075 | universal stress protein/lysophospholipase |
| * | CP000730 | 36,269 | 0 | C | T | 56.9% | 54.8 / inf | 353 | A95T (GCA→ACA) | tpn | IS431mec transposase |
| * | CP000730 | 35,876 | 0 | C | T | 53.8% | 17.5 / 66.2 | 52 | intergenic (+107/+1) | rlmH/tpn | hypothetical protein/IS431mec transposase |
| * | CP000730 | 36,413 | 0 | C | T | 53.0% | 20.5 / inf | 271 | V47I (GTC→ATC) | tpn | IS431mec transposase |
| * | CP000730 | 36,315 | 0 | G | A | 52.7% | 23.9 / inf | 388 | Y79Y (TAC→TAT) | tpn | IS431mec transposase |
| * | CP000730 | 512,643 | 0 | A | G | 50.6% | ‑2.2 / 110.5 | 77 | intergenic (+711/‑150) | recR/rrs1 | recombination protein RecR/16S ribosomal RNA |
| * | CP000730 | 1,929,875 | 0 | T | C | 50.0% | 4.8 / 89.4 | 64 | intergenic (‑958/‑210) | USA300HOU_1794/USA300HOU_1796 | hypothetical protein/hypothetical protein |
| * | CP000730 | 1,929,843 | 0 | A | . | 48.5% | 126.8 / 137.0 | 66 | intergenic (‑926/‑242) | USA300HOU_1794/USA300HOU_1796 | hypothetical protein/hypothetical protein |
| * | CP000730 | 1,929,848 | 0 | C | A | 48.5% | 30.8 / 91.6 | 66 | intergenic (‑931/‑237) | USA300HOU_1794/USA300HOU_1796 | hypothetical protein/hypothetical protein |
| * | CP000730 | 1,929,872 | 0 | G | A | 48.5% | 12.9 / 88.5 | 66 | intergenic (‑955/‑213) | USA300HOU_1794/USA300HOU_1796 | hypothetical protein/hypothetical protein |
| * | CP000730 | 1,929,873 | 0 | C | A | 48.5% | 26.7 / 94.4 | 66 | intergenic (‑956/‑212) | USA300HOU_1794/USA300HOU_1796 | hypothetical protein/hypothetical protein |
| * | CP000730 | 1,929,861 | 0 | T | C | 47.8% | ‑6.3 / 97.2 | 67 | intergenic (‑944/‑224) | USA300HOU_1794/USA300HOU_1796 | hypothetical protein/hypothetical protein |
| * | CP000730 | 1,929,867 | 0 | G | T | 47.8% | 34.6 / 95.8 | 67 | intergenic (‑950/‑218) | USA300HOU_1794/USA300HOU_1796 | hypothetical protein/hypothetical protein |
| * | CP000730 | 1,929,870 | 0 | A | C | 47.8% | 4.0 / 116.9 | 67 | intergenic (‑953/‑215) | USA300HOU_1794/USA300HOU_1796 | hypothetical protein/hypothetical protein |
| * | CP000730 | 1,929,842 | 0 | T | . | 47.1% | 137.2 / 135.6 | 68 | intergenic (‑925/‑243) | USA300HOU_1794/USA300HOU_1796 | hypothetical protein/hypothetical protein |